Highly sensitive molecular diagnosis of prostate cancer using surplus material washed off from biopsy needles

R Bermudo1,2, D Abia3, A Mozos4,7, E García-Cruz5, A Alcaraz1,5,6, ÁR Ortiz*3, TM Thomson*2,8 and PL Fernández*1,4,6,9

1Institut d’Investigacions Biomèdiques August Pi i Sunyer, c. Villarroel 170, 08036, Barcelona, Spain; 2Department of Cell Biology, Institute for Molecular Biology, Science Research Council, c. Baldí Reixac 15-21, 08028, Barcelona, Spain; 3Bioinformatics Unit, Centro de Biología Molecular Severo Ochoa, Science Research Council and Universidad Autonoma de Madrid, c. Nicolás Cabrera 1, Cantoblanco, 28049, Madrid, Spain; 4Department of Pathology, Hospital Clinic, c. Villarroel 170, 08036, Barcelona, Spain; 5Department of Urology, Hospital Clinic, c. Villarroel 170, 08036, Barcelona, Spain; 6School of Medicine, University of Barcelona, c. Casanova 143, 08036, Barcelona, Spain

INTRODUCTION: Currently, final diagnosis of prostate cancer (PCa) is based on histopathological analysis of needle biopsies, but this process often bears uncertainties due to small sample size, tumour focality and pathologist’s subjective assessment.

METHODS: Prostate cancer diagnostic signatures were generated by applying linear discriminant analysis to microarray and real-time RT–PCR (qRT–PCR) data from normal and tumoural prostate tissue samples. Additionally, after removal of biopsy tissues, material washed off from transrectal biopsy needles was used for molecular profiling and discriminant analysis.

RESULTS: Linear discriminant analysis applied to microarray data for a set of 318 genes differentially expressed between non-tumoural and tumoural prostate samples produced 26 gene signatures, which classified the 84 samples used with 100% accuracy. To identify signatures potentially useful for the diagnosis of prostate biopsies, surplus material washed off from routine biopsy needles from 53 patients was used to generate qRT–PCR data for a subset of 11 genes. This analysis identified a six-gene signature that correctly assigned the biopsies as benign or tumoural in 92.6% of the cases, with 88.8% sensitivity and 96.1% specificity.

CONCLUSION: Surplus material from prostate needle biopsies can be used for minimal-size gene signature analysis for sensitive and accurate discrimination between non-tumoural and tumoural prostates, without interference with current diagnostic procedures. This approach could be a useful adjunct to current procedures in PCa diagnosis.

Keywords: diagnosis; linear discriminant analysis; prostate cancer; real-time RT–PCR; gene signature; needle biopsy

Early diagnosis of prostate cancer (PCa), the second most common cancer worldwide, is based on digital rectal examination and the determination of prostate-specific antigen (PSA) blood levels, followed by transrectal biopsy, an invasive procedure with potential side effects, mainly infections and haemorrhage (Ferlay et al, 2004). This combination of procedures is fraught with diagnostic uncertainties, such that ~75% of biopsies prompted by an elevated PSA are subsequently found not to bear detectable PCa and around 15% of the patients with low PSA levels are subsequently found to harbour a tumour (Thompson et al, 2004; Schroder et al, 2009). In addition, the frequent focal involvement and small volume of tumours can hamper a definitive diagnosis. To increase diagnostic accuracy, an estimated 20% of biopsies are submitted to immunohistochemical detection of basal-cell markers and AMACR (α-methylacyl-CoA racemase). Still, up to 25% of these biopsies remain without a definitive diagnosis due to inconclusive results or tissue exhaustion (Browne et al, 2004; Montironi et al, 2006) and are classified as atypical small acinar proliferation (ASP). Therefore, until more sensitive and specific procedures are developed, it is mandatory to extract the maximum information from such explorations.

The use of biological material that remains associated with aspiration or biopsy needles has been explored in different organs for morphological analysis, flow cytometry or molecular testing (Perry and Johnston, 1985; Stomper et al, 1998, 2001; Akimaru et al, 2004). In this study, we have explored the application of gene signatures on material washed off from biopsy needles in the diagnostic evaluation of prostate biopsies.

MATERIALS AND METHODS

Linear discriminant analysis

We previously identified a set of 318 genes whose expression levels are highly discriminant between malignant and normal prostate tissues (Bermudo et al, 2008). Microarray data sets from this study are deposited in the array express repository under accession number E-MEXP-1331. To the microarray data for the 27
of that study we added data for 57 unrelated samples, generated by Liu et al. (2006). The resulting data set for all 84 samples (19 non-tumoural and 65 tumoural) was normalised with the robust multiarray average method and then quantile normalised (Irizarry et al., 2003, 2006). To identify minimal-size genesets capable of optimally discriminating between malignant and normal samples, we considered the expression values for the set of 318 genes in these 84 samples. We performed linear discriminant analysis (LDA) using three iterative approaches, two backward stepwise (a deterministic mode and a stochastic mode) and one forward stepwise. For the deterministic backward stepwise mode, we removed from the 318 geneset at each step the 10% of genes with the lowest contribution to the model and measured the classification accuracy at each step by leave-one-out-cross validation (LOOCV). For the stochastic backward stepwise mode, 50% of the genes from the group of the 20% least significant genes were randomly removed at each step, and the classification accuracy tested by LOOCV. We ran five trials in this way. For the forward stepwise LDA approach, data from all samples were used to generate 10 training-set and test-set pairs by randomly selecting 75% of the samples to form the training set, the remaining samples forming the test set. The best discriminant pair of genes from each possible pairwise combinations was initially selected from the training set as implemented in the MASS (Irizarry et al., 2006) package of R (Venables and Ripley, 2002), tested by LOOCV and used as a seed for increasing the number of genes, one at each round, keeping those that performed best as assessed by LOOCV. Genes with equal discriminating power were monitored and used to build all possible alternative models. The performance of the models generated in the training sets was measured by LOOCV, and those yielding a 100% classification success were applied to determine their classification accuracy on the corresponding test sets. The Fisher’s linear discriminant function was calculated for each generated model.

For LDA of transcriptional data for 11 genes differentially expressed between non-tumoural and tumoural prostate tissues, we used data obtained from the real-time RT–PCR (qRT–PCR) analysis of samples washed off from prostate biopsy needles (see Materials and Methods). An LDA iterative forward stepwise mode was applied as described before to mean ΔCt data for these 11 genes in 28 tumoural and 26 non-tumoural samples.

### Table 1 Clinical and histological characteristics of the patients whose samples were used for simulated prostate biopsies

| Tumoural samples | Normal samples
|------------------|------------------|
| Number of samples | 37               |
| Number of patients | 27              |
| Mean age (years) | 62.32 (49–72)    |
| Mean PSA (ng/ml) | 10.13 (3.09–55.8) |
| Median PSA (ng/ml) | 8                |
| Mean ratio free PSA/total PSA (%) | 15.3 (3.4–51.4) |
| Median ratio free PSA/total PSA (%) | 10               |
| Gleason score (number of patients) | 5 3 6 3 7 17 8 2 9 |
| TNM stage (number of patients) | T2 15 T3 12 |
| % of carcinoma in the tissue core | 38.4% (10–90) |

**Abbreviation:** PSA = prostate-specific antigen. *Normal samples were obtained from tumour-free prostates from nodular hyperplasias and radical prostatectomies. **Data not available for two patients. ***Data not available for 10 patients. ****Mean content of tumoural glands relative to the whole tissue.

### Processing of residual material recovered from simulated prostate biopsy needles

Freshly procured specimens were sampled with biopsy needles, which were inserted once in the peripheral zone of each lobe. The resulting tissue cores were removed for histopathological examination, the empty needle was washed in RNA later (Ambion, Austin, TX, USA) and the recovered material stored until further processing. Thirty-seven samples thus obtained from 27 radical prostatectomies with adenocarcinoma were used as tumoural cases, in which the simulated biopsy cores contained tumoural glands. Eleven samples from tumour-free prostates were used as non-tumoural cases (Table 1). Total RNA was isolated using the RNeasy Kit (Qiagen, Valencia, CA, USA) and transcripts quantified by qRT–PCR (Table 2).

### Processing of prostate and colon tissues

Prostate tissues were obtained from patients undergoing radical prostatectomy for clinically localised prostate adenocarcinoma (14 non-tumoural and 34 tumoural; Table 3). Four normal colon mucosa samples were obtained from colectomy specimens from patients with colorectal adenocarcinoma. Total RNA was isolated as described before from tissue cryosections and used for qRT–PCR (Table 2). All tissue samples were obtained from the Tumour Bank-Biobank of the Hospital Clinic-IDIBAPS, Barcelona, and cleared for research use after local review board evaluation in compliance with current Spanish laws, including informed written consent.

### Processing of material washed off from transrectal prostate biopsy needles

Transrectal prostate biopsies were performed in patients with PSA levels >4 ng ml⁻¹ with a 10-core scheme, using a single needle per patient. After each puncture, the tissue cylinder was removed and the empty needle was briefly washed in sterile saline solution in individual containers. All five tissue cores from one lobe were processed jointly for histopathology and given a single diagnosis. Washed-off samples were obtained from 27 patients diagnosed with adenocarcinoma in the biopsy cores and 26 patients with a non-tumoural diagnosis (Table 4). The latter had at least one
### Table 2: Genes used in real-time RT–PCR analyses and their corresponding TaqMan probes

| Gene symbol | Description                                   | Experiment | Assay ID          |
|-------------|-----------------------------------------------|------------|-------------------|
| ABCC4       | ATP-binding cassette, subfamily C (CFTR/MRP), member 4 | 2, 3       | Hs00195260_m1     |
| AMACR       | α-Methylacyl-CoA racemase                      | 1, 2, 3    | Hs00204885_m1     |
| EPCAM       | Epithelial cell adhesion molecule              | 1, 2, 3    | Hs00158980_m1     |
| HPN         | Hepsin (transmembrane protease, serine 1)     | 1, 2, 3    | Hs00170996_m1     |
| MYO6        | Myosin VI                                     | 2, 3       | Hs00192265_m1     |
| CSTA        | Cystatin A (stefin A)                          | 2, 3       | Hs00193257_m1     |
| DST         | Dystonin                                      | 2, 3       | Hs00794953_m1     |
| EPHA2       | EPH receptor A2                                | 2, 3       | Hs00171656_m1     |
| KRT5        | Keratin 5                                     | 1, 2, 3    | Hs00361185_m1     |
| LAMB3       | Laminin β3                                    | 1, 2, 3    | Hs00165078_m1     |
| SNAI2       | Snail homologue 2 (Drosophila)                | 2, 3       | Hs00161904_m1     |
| RN1851      | RNA, 18S ribosomal 1                          | 1, 2, 3    | 4342379-18S/Hs99999901_s1 |

Abbreviation: RT–PCR = reverse transcriptase polymerase chain reaction. aExperiment in which each probe was used: 1: washed-off samples from simulated prostate biopsy needles; 2: whole tissue samples from prostate and colon; 3: washed-off samples from transrectal prostate biopsy needles. bManufacturer’s probe ID.

### Table 3: Clinical and histological characteristics of prostate whole tissue samples

| Tumoural samples | Normal samples |
|------------------|---------------|
| Number of patients | 34            | Number of patients | 14 |
| Mean age (years)  | 64.3 (50–74)  | Mean age (years)   | 67 (56–73) |
| Mean PSA (ng ml⁻¹) | 7.16 (3.58–19) | Mean PSA (ng ml⁻¹) | 7.11 (4.6–10) |
| Median PSA (ng ml⁻¹) | 6.8           | Median PSA (ng ml⁻¹) | 7.3 |
| Mean ratio free PSA/total PSA (%) | 10.73 (6–23) | Mean ratio free PSA/total PSA (%) | 10.9 (7–15) |
| Median ratio free PSA/total PSA (%) | 9.6         | Median ratio free PSA/total PSA (%) | 10.5 |
| Gleason score (number of patients) | 5, 6, 7, 8, 9 | Percentage of non-tumoural epithelium (%) | 43 |
| TNM stage | 1, 2, 3 | |
| Tumoural epithelium (%) | 60 | Percentage of non-tumoural epithelium (%) | 43 |

Abbreviation: PSA = prostate-specific antigen. aData not available for one patient. bData not available for eight patients. cData not available for 14 patients. dMean content of tumoural glands relative to the whole tissue. eMean content of non-tumoural glands relative to the whole tissue.

### Table 4: Clinical and histological characteristics of the patients whose prostate biopsy needles were used for residual sample retrieval and analysis

| Tumoural wash-off samples | Normal wash-off samples |
|---------------------------|-------------------------|
| Number of patients | 27                      | Number of patients | 26 |
| Mean age (years)  | 66 (52–84)              | Mean age (years)   | 67 (57–78) |
| Mean PSA (ng ml⁻¹) | 648 (1.47–10,230)       | Mean PSA (ng ml⁻¹) | 132.4 (2.11–79) |
| Median PSA (ng ml⁻¹) | 8            | Median PSA (ng ml⁻¹) | 8.14  |
| Mean ratio free PSA/total PSA (%) | 18.1 (6.9–34) | Mean ratio free PSA/total PSA (%) | 16.6 (9–24.7) |
| Median ratio free PSA/total PSA (%) | 15.9 | Median ratio free PSA/total PSA (%) | 17.8 |
| Gleason score (number of patients) | 6, 7, 8, 9, 10 | |
| Tumoural wash-off samples | 10 |
| Mean % of carcinoma in the tissue core | 53.8 (<5–90) |

Abbreviation: PSA = prostate-specific antigen. aFor one patient, both lobes were analysed. bData not available for eight patients. cData not available for 14 patients. dData not available for six patients. eData not available for 10 patients. fMean content of tumoural glands relative to the whole tissue.
additional benign prostate biopsy diagnosis, either previous or subsequent to the biopsy used in this study. For each patient, qRT–PCR analysis was performed on material washed off from one lobe, selecting for tumoural samples the lobe with the highest content of tumour, and for non-tumoural samples the lobe with representative benign histology. Washed-off samples were centrifuged, the pellet resuspended in RNA lysis buffer (Qiagen) and stored at −80°C until use. Samples washed off from each needle puncture were processed separately to isolate total RNA followed by qRT–PCR (Table 2).

Real-time RT–PCR
Total RNA was reverse-transcribed and cDNAs used for qRT–PCR on custom-designed TaqMan Low Density Arrays (Applied Biosystems, Foster City, CA, USA) in an ABI PRISM 7900HT instrument. Table 2 summarises probe information. Data were analysed using the SDS 2.3 software (Applied Biosystems). For simulated biopsies, relative transcript quantification was determined by the ΔΔCt method. For colonic and prostatic tissues, ΔCt data were used to build hierarchical clusters by UPGMA (unweighted pair group method with arithmetic mean) (Sneath and Sokal, 1973). P-value was used to calculate probability values for each cluster, using multiscale bootstrap resampling, with 10,000 simulations (Suzuki and Shimodaira, 2006). A cluster was considered as stable when the AU (approximately unbiased) P-values obtained were >95. For material washed off from transrectal prostate biopsy needles, individual washed-off samples with low input RNA (Ct (185) > 18.5) were discarded, cases with less than three washed-off samples with available valid qRT–PCR data were excluded from the analyses and mean ΔCt values of the available washed-off samples for each case were used for LDA.

RESULTS

Generation of optimal gene signatures that discriminate non-tumoural from tumoural prostate tissues

With the aim of identifying minimal-size gene signatures that discriminate benign from tumoural prostate tissue, we applied LDA, which identifies a group of variables (here, gene expression levels) constituting a subset of a broader group, that can explain the data differences observed between two classes of entities (here, non-tumoural and tumoural samples). The linear function related to this signature can be used to assign new samples to its corresponding class. We have applied two backward stepwise and one forward stepwise approaches. The first two begin by building a model with all available genes and at each step remove a percentage of those that contribute less to the prediction of group membership, and the last builds up the model by testing all genes at each step and keeping the one that produces the most accurate classification for the next round.

For our LDA analyses, we considered as a starting point the 318 genes selected from a previous work (Bermudo et al., 2008) as those with the most significant differential expression between benign and adenocarcinoma prostate tissue samples. To the microarray data for the original 27 samples of that study we added data for 57 unrelated samples, generated by Liu et al. (2006), resulting in a combined expression data set for a total of 84 samples, which included 19 non-tumoural and 65 tumoural samples. Linear discriminant analysis applied to the data for these 318 genes in all 84 samples produced 26 distinct signatures, all of which achieved 100% accuracy in classifying all 84 prostate samples as either benign or tumoural. Figure 1 shows the performance of the most interesting model obtained by each LDA approach, which corresponds to the one containing the smallest numbers of genes. With the deterministic backward stepwise approach, we obtained 17 models containing from 9 to 57 genes. Because this approach was initiated with a relatively high number of genes, 318, the contribution to sample classification of many genes in the first few iterative rounds was quite low, which could cause the loss of useful genes during the first rounds of iteration. Therefore, we have also applied a second approach consisting in the removal of genes, at each step, in a stochastic manner, from the group of less significant genes. In the backward stochastic approach, we obtained three models, containing from 18 to 23 genes. Supplementary Tables 1 and 2 show the genes contained in these models and the LDA loadings calculated for each gene.

Using the forward stepwise LDA approach, we generated and tested the models derived from all possible gene pairs independently for each of the 10 training sets. We obtained 49 gene pairs, ranked by their LOOCV classification accuracy, of which two pairs were repeated in three different training sets and five pairs in two training sets, while the remaining pairs were unique. The number of times that each gene appears in any of the selected pairs is summarised in Supplementary Table 3. Each of these pairs was used as a seed for its corresponding training set, and one gene was added at each step of the process. We collected the models generated (n = 776) that achieved 100% classification accuracy as confirmed by LOOCV, and tested them on their corresponding test sets. We found that six models, each constituted by four genes, also classified perfectly (100% accuracy) those samples in three of the training-set/test-set groups (Supplementary Table 4).

These results show that different statistical approaches yield many minimal-size gene sets that allow excellent discrimination between malignant and normal prostate tissues, based on their gene expression profiles.

Classification of prostate biopsies as benign or tumoural by transcriptional profiling of surplus material from biopsy needles

Microarray hybridisation is not a first-choice technology in current clinical practice because of sample size requirements and cost issues. Practical diagnostic signatures would be those that can be used with alternative techniques, such as qRT–PCR. Given the significant differences in target sequences and intrinsic technological features, if microarray data are used as a starting point for these molecular diagnostic signatures, they must be first validated by qRT–PCR if this technique is to be applied for diagnostic purposes. Because our discriminant model building based on 318 genes generated multiple optimal signatures, we next applied LDA by departing from a reduced subset of 11 genes that had been carefully validated by qRT–PCR (Bermudo et al., 2008), thus offering a significant gain in confidence in their discriminant capacity over genes not validated by this technique. Second, because our aim was to generate gene signatures with clinical applicability, while avoiding any interference with standard clinical practice, we decided to perform transcriptional profiling solely on the biological material that may remain attached to the biopsy needle, which is normally discarded after biopsy, leaving the biopsy cylinder entirely for routine diagnostic histopathological assessment.

As a preliminary step to assess the feasibility of obtaining meaningful transcriptional profiles from such material, we simulated needle biopsies on prostates from radical prostatectomies, processed the tissue cores for pathological evaluation and washed the resulting empty biopsy needles to produce the material (needle ‘wash-offs’) for transcriptomic analysis. We confirmed that the amount and integrity of total RNA was adequate for qRT–PCR analysis (RNA integrity number higher than 5), and used these samples for qRT–PCR quantification of transcripts for five genes well known as differentially expressed in PCa: AMACR (Luo et al., 2002; Rubin et al., 2002), HFPN (Dhanasekaran et al., 2001; Luo et al., 2001; Magee et al., 2001) and EPCAM (Strnad et al., 1999;
Figure 1  Linear discriminant analysis applied to microarray data for 318 genes discriminant between normal and tumoural prostate samples generates minimal-size gene signatures diagnostic of PCa. Results of the best models generated by each of the LDA approaches used: (A) backward stepwise deterministic, (B) backward stepwise stochastic and (C) forward stepwise. Plots show the performance of the models for the 65 tumoural (filled circles) and 19 normal (empty circles) samples analysed. LDA scores obtained by each sample are represented on the y axis. Samples are classified as tumoural or non-tumoural, when their corresponding LDA score are above or under the model threshold (dashed line), respectively. Note that each LDA model yields its own independent class-discriminant threshold.

Figure 2  A highly sensitive and specific minimal-size gene signature diagnostic of PCa generated by LDA applied to qRT–PCR data for transrectal prostate biopsy needle wash-off samples. (A) Material washed off from simulated prostate biopsy needles is suitable for real-time RT–PCR transcript quantification. The bar plots represent the ratios of tumoural vs non-tumoural wash-off samples, showing the overexpression in carcinomatous washed-off samples of AMACR, HPN and EPCAM, as well as the underexpression of KRT5 and LAMB3. Non-tumoural washed-off samples were obtained from tumour-free prostates from nodular hyperplasias or radical cystoprostatectomies. Tumoural washed-off samples were obtained from radical prostatectomies diagnosed of adenocarcinoma and whose simulated biopsy cores contained tumoural glands. *P-value < 0.001. (B) Samples from colonic tissues display expression profiles for 11 selected genes that are distinct from normal and tumoural prostate samples. A hierarchical cluster was built with expression data obtained by qRT–PCR from non-tumoural colon (C–N) and tumoural (P–T) and non-tumoural (P–N) prostate samples. Pclust analysis was used to assess the uncertainty of hierarchical clustering, obtaining AU values for each cluster, which show cluster stability when AU > 95. Prostate data correspond to mean values from the available prostate samples. AU values are shown at the main branches of the hierarchical tree, illustrating that colonic samples display a gene expression profile that clearly differentiate them (AU > 95) from all prostatic samples. (C) A highly sensitive and specific minimal-size gene signature diagnostic of PCa generated by LDA applied to qRT–PCR data for transrectal prostate biopsy needle wash-off samples. Results of the six-gene model generated by LDA, capable of discriminating wash-off samples from tumoural prostate biopsies (n = 28) and non-tumoural ones (n = 26). LDA scores obtained by each sample are represented in the y axis. Samples are classified as tumoural (filled circles) or non-tumoural (empty circles), when their corresponding LDA score is above or under the model's threshold (dashed line), respectively.

Poczatek et al., 1999), overexpressed in PCa, and LAMB3 (Hao et al., 1996) and KRT5 (Ordonez, 1998; Abrahams et al., 2002), underexpressed in PCa. Our results show that three of these genes are also significantly differentially expressed in material washed off from simulated biopsy needles (Figure 2A), demonstrating the suitability of this material for sensitive transcript quantification.
In transrectal prostate biopsies, the needle traverses rectal tissues, is contaminated with peripheral blood and finally pierces the prostate capsule before reaching the prostatic glands and stroma. These tissues could potentially distort the profiles generated for the scarce biological material contained in needle washes and thus limit the discriminant power of gene signatures. Therefore, we analysed the expression of the 11-gene set in non-tumoural colorectal tissue, the major contaminant in actual prostate biopsies. The resulting profiles were clearly different (AU > 95) from those for benign or tumoural prostate tissues (Figure 2B), suggesting that colorectal tissue that might attach to biopsy needles should not introduce a significant bias on prostate-specific transcriptional profiles.

We next assessed the applicability of gene signatures to residual material from actual prostate needle biopsies, for which we analysed material washed off from biopsy needles used on a total of 53 patients (Table 4). Transcript levels for the 11 genes were quantified by qRT-PCR and the resulting data used for LDA model building, in which the expression profiles were benchmarked against the histopathological diagnosis assigned to the corresponding biopsy tissues. The best discriminant model contained six genes (Table 5), four of which were overexpressed (ABCC4, AMACR, HPN and MYO6) and two underexpressed (CSTA and LAMB3) in PCa. By applying LDA with this gene signature, 25 of 28 samples with a tumoural histological diagnosis were assigned a tumoural molecular status, and 25 of 26 samples that lacked tumoural glands by histological evaluation were molecularly classified as non-neoplastic. Thus, our six-gene signature applied to biopsy needle residual material showed a 92.6% concordance with the pathological diagnosis of the corresponding biopsy cylinders, with a specificity of 88.8% and a specificity of 96.1% (Figure 2C).

Interestingly, nine of the biopsies whose corresponding washed-off samples were used required additional immunohistochemical analyses to reach a definitive histopathological diagnosis of PCa (six cases) or benign tissue (three cases). Eight out of these nine samples (88.8%) were correctly classified as tumoural or non-tumoural by the six-gene signature. These results suggest that transcriptional profiling of residual material recovered from prostate biopsy needles can achieve a diagnostic accuracy (tumoural vs non-tumoural) comparable to the combination of routine histological assessment and immunohistochemical analysis of biopsy cylinders.

**DISCUSSION**

Two important challenges in PCa diagnosis are the limitations of current serum markers for clinical screening and the limited sensitivity of biopsy techniques, both with a significant proportion of false or indeterminate results. The use of minimal genesets as molecular classifiers for tumour diagnosis or subclassification is therefore being actively explored in several neoplasms. We approached this problem by applying LDA to a set of 318 genes, which yielded multiple optimal signatures that discriminate non-tumoural from tumoural prostate tissues. The high probability of finding different discriminant solutions is rooted in the nature of transcriptomics, which considers numerous variables, thus increasing the likelihood of arriving at multiple discriminant models (Ein-Dor *et al*, 2005; Grate, 2005; Dougherty and Brun, 2007; Guillot *et al*, 2007). Many of these signatures contained non-overlapping genes, which were not necessarily those most differentially expressed between malignant and normal tissues. This is because genes with similar expression profiles across samples provide redundant information and are therefore discarded in the model building process. This could partially explain the divergences found between different studies describing diagnostic and prognostic signatures.

The main objective of this study was to maximise the diagnostic information obtained from prostate biopsies, for which we tested the applicability of gene signatures on surplus material obtained from biopsy needles that is normally discarded. The most discriminant model generated for such samples contained six genes, all previously associated with cancer, which confirms our signature an additional functional relevance (Tomlins *et al*, 2007; Bermudo *et al*, 2008). This model showed 92.6% concordance between the molecular profiling of needle washes and the histopathological diagnosis of the corresponding biopsy cylinders. Therefore, our results indicate that molecular profiling performed on biological material that is routinely discarded, saline washes of biopsy needles, can achieve a diagnosis of prostate malignancy with an accuracy at least comparable to histopathological assessment of biopsy tissues. The fact that three cases were incorrectly classified as non-tumoural by molecular profiling might be explained by an insufficient representation of tumoural cells in that washed-off samples, given that the tissue from the biopsy and the washed-off sample are expected to be complementary but different samples. Due to ethical constraints, we have not performed molecular profiling on the biopsy cylinders. However, given the high sensitivity and specificity of our molecular diagnostic approach on residual material, it is reasonable to assume that profiling of the biopsy tissues themselves should afford even higher levels of diagnostic accuracy.

The high diagnostic accuracy of our approach is further highlighted by the fact that, of the six biopsies (16.6%) required immunohistochemical analysis in order to reach histopathological diagnosis, of which eight were initially diagnosed correctly by our molecular profiling approach. Of these cases, the only case initially classified as non-tumoural histologically but as tumoural by our approach might be found histologically positive for prostate adenocarcinoma in subsequent biopsies, which are not presently available.

Our six-gene signature was robust, discriminating benign from malignant samples independent of Gleason scores and tumour cell representations, which ranged from < 5% to 90% of the total tissue. This suggests that it could be a useful adjunct for the management of biopsies with uncertain diagnoses. In Europe, the annual number of 382 000 estimated new cases of PCa in 2008 implying that > 1.5 million biopsies were performed, of which ~ 300 000 could not be diagnosed by morphological criteria alone and required additional immunohistochemical assays (Ferlay *et al*, 2010). Importantly, even after immunohistochemical analysis, > 70 000 cases were likely diagnosed as ASAP, which is associated with a PCa risk of around 40% in subsequent explorations (Montironi *et al*, 2006). Many of these diagnoses could potentially have been avoided with the application of complementary methods to enhance the sensitivity of routine biopsy diagnostic procedures.

We propose a hypothetical diagnostic course of action in which material washed off from prostate biopsy needles could be initially preserved, which implies a fast and economic way of collecting samples that are normally discarded with the biopsy needle.
ACKNOWLEDGEMENTS

We gratefully acknowledge the expert assistance of urological clinicians at the Hospital Clínic de Barcelona in the collection of the wash-off samples from transrectal ultrasound-guided prostate biopsies, and the help of Mónica Marín and Eva Fernández in simulated biopsy samples procurement. This study was supported by grants from the Ministerio de Ciencia e Innovación (PI080274), Fundación Marató TV3, Ministerio de Educación (GEN2001-4856-C13, GEN2001-4865-C13-10 and SAF2005-05109), Ministerio de Sanidad (PI020231), Red Temática de Cáncer of the Instituto Carlos III (ISCIII-RETIC RD06/0020), Xarxa de Bancs de Tumors de Catalunya-ICO (XBTC) and Fundación Ramón Areces.

Conflict of interest

RB, DA, ARO, PLF and TMT are co-inventors in a patent application related to part of the results described in this manuscript.

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)

REFERENCES

Abrahams NA, Ormsby AH, Brainard J (2002) Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histopathology 41: 35–41

Akimaru K, Yokomuro S, Aimoto T, Yoshiha H, Uchida E, Tajiri T (2004) ‘Tumor marker measurements of cells in a fine needle used for aspiration cytology. Anal Quant Cytol Histol 26: 249 – 254

Bermudo R, Abia D, Ferrer B, Nayach I, Benguria A, Zabalos A, del Roy J, Miro R, Campo E, Martinez AC, Ortiz AR, Fernandez PL, Thomson TM (2008) Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer. BMC Cancer 8: 315

Browne TJ, Hirsch MS, Brooksby G, Welch WR, Loda MF, Rubin MA (2004) Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol 35: 1462 – 1468

Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinniyan AM (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412: 822 – 826

Dougherty ER, Brun M (2007) On the number of close-to-optimal feature sets. Cancer Inform 2: 189 – 196

Ein-Dor L, Kela I, Getz G, Givol D, Domany E (2005) Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21: 171 – 178

Fairly J, Bray E, Pisani P, Parkin DM (2004) GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5 (version 2.0), IARC Press: Lyon

Fairly J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765 – 781

Grate LR (2005) Many accurate small-discriminatory feature subsets exist in microarray transcript data: biomarker discovery. BMC Bioinformatics 6: 97

Guillot G, Olsson M, Benson M, Rudemo M (2007) Discrimination and scoring using small sets of genes for two-sample microarray data. Math Biosci 205: 195 – 203

Hao J, Yang Y, McDaniel KM, Dalkin BL, Cress AE, Nagle RB (1996) Differential expression of laminin 5 (alpha 3 beta 3 gamma 2) by human malignant and normal prostate. Am J Pathol 149: 1341 – 1349

Irizarry RA, Gautier L, Bolstad ML (2006) Methods for Affymetrix Oligonucleotide Arrays. R package version 1.12.1

Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249 – 264

Liu P, Ramachandran S, Ali Seyid M, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jave DL, Moreno CS (2006) Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 66: 4011 – 4019

Luo J, Duggan DJ, Chen Y, Sauvaget J, Ewing CM, Bittner ML, Trent JM, Isaacs WB (2001) Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61: 4683 – 4688

Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandasu S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM (2002) Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62: 2220 – 2226

Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, Catalona WJ, Watson MA, Milbrandt J (2001) Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61: 5692 – 5696

Montironi R, Scattoni V, Mazzucchelli R, Lopez-Beltran A, Bostwick DG, Montorsi F (2006) Atypical foci suspicious but not diagnostic of malignancy in prostate needle biopsy (also referred to as ‘atypical small acinar proliferation suspicious for but not diagnostic of malignancy’). Eur Urol 50: 666 – 674

Ordonez NG (1998) Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 22: 1215 – 1221

Perry MD, Johnston WW (1985) Needle biopsy of the liver for the diagnosis of nonneoplastic liver diseases. Acta Cytol 29: 385 – 390

Pocztak RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, Grizzle WE (1999) Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 162: 1462 – 1466

Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sandra MG, Pienta KJ, Ghosh D, Chinniyan AM (2002) alpha-Methylacyl Coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287: 1662 – 1670

Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Aisack S, Nelen V, Kwikowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1330 – 1338

Sneath PH, Sokal RR (1973) Numerical Taxonomy: The Principles and Practice of Numerical Classification. W.H. Freeman: San Francisco

Stomper PC, Budnick RM, Stewart CC (1998) Breast stereotactic core biopsy washings: abundant cell samples from clinically occult lesions for simulated biopsy samples procurement. Proc Natl Acad Sci USA 95: 13836 – 13840

Stromper PC, Budnick RM, Stoler DL (2001) Stereotactic core biopsy breast and blood cell by-products: a source of material for molecular genetics research – initial experience. Radiology 218: 881 – 885
Strnad J, Hamilton AE, Beavers LS, Gamboa GC, Apelgren LD, Taber LD, Sportsman JR, Bumol TF, Sharp JD, Gadski RA (1989) Molecular cloning and characterization of a human adenocarcinoma/epithelial cell surface antigen complementary DNA. *Cancer Res* **49:** 314–317

Suzuki R, Shimodaira H (2006) Pvclust: an R package for assessing the uncertainty in hierarchical clustering. *Bioinformatics* **22:** 1540–1542

Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman Jr CA (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level $\leq 4.0$ ng per milliliter. *N Engl J Med* **350:** 2239–2246

Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM (2007) Integrative molecular concept modeling of prostate cancer progression. *Nat Genet* **39:** 41–51

Venables WN, Ripley BD (2002) *Modern Applied Statistics with S*, Fourth edn. Springer: New York

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.